These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27790000)

  • 1. Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome.
    Quartier P
    Open Access Rheumatol; 2011; 3():9-18. PubMed ID: 27790000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).
    Gillespie J; Mathews R; McDermott MF
    J Inflamm Res; 2010; 3():1-8. PubMed ID: 22096352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rilonacept in the treatment of chronic inflammatory disorders.
    McDermott MF
    Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
    Church LD; Savic S; McDermott MF
    Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Arnold DD; Yalamanoglu A; Boyman O
    Front Immunol; 2022; 13():888392. PubMed ID: 35874710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome.
    Dhimolea E
    Appl Clin Genet; 2011; 4():21-7. PubMed ID: 23776364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.
    Kuemmerle-Deschner JB; Haug I
    Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):315-29. PubMed ID: 24294305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).
    Toker O; Hashkes PJ
    Biologics; 2010 May; 4():131-8. PubMed ID: 20531965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
    Lipsker D; Lenormand C
    Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.
    Malcova H; Strizova Z; Milota T; Striz I; Sediva A; Cebecauerova D; Horvath R
    Front Immunol; 2020; 11():619257. PubMed ID: 33603750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cryopyrin-associated periodic syndrome].
    Kümmerle-Deschner JB
    Z Rheumatol; 2012 Apr; 71(3):199-208. PubMed ID: 22527214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IL-1 antagonists].
    Kötter I; Horneff G
    Z Rheumatol; 2010 Sep; 69(7):581-93. PubMed ID: 20703489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.